TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+3.73%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$3.11B
AUM Growth
+$3.11B
(+0.92%)
Cap. Flow
+$26.2M
Cap. Flow
% of AUM
0.84%
Top 10 Holdings %
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34
Top Buys
| 1 |
Rallybio
RLYB
|
$37.6M |
| 2 |
Guardant Health
GH
|
$28.7M |
| 3 |
Idexx Laboratories
IDXX
|
$27.9M |
| 4 |
Amgen
AMGN
|
$23.7M |
| 5 |
AstraZeneca
AZN
|
$21.9M |
Top Sells
| 1 |
Elevance Health
ELV
|
$34.7M |
| 2 |
ResMed
RMD
|
$32.6M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$22.2M |
| 4 |
DexCom
DXCM
|
$21.8M |
| 5 |
Ascendis Pharma
ASND
|
$13.7M |
Sector Composition
| 1 | Healthcare | 96.51% |
| 2 | Real Estate | 2.72% |
| 3 | Industrials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $177M | 5.69% | 459,456 -6,321 | -1% | -$2.43M |
|
|
2
Amgen
AMGN
$155B
| $122M | 3.94% | 574,918 +111,513 | +24% | +$23.7M |
|
3
UnitedHealth
UNH
$281B
| $120M | 3.85% | 306,129 -9,419 | -3% | -$3.68M |
|
4
Gilead Sciences
GILD
$140B
| $119M | 3.84% | 1,708,065 +73,280 | +4% | +$5.12M |
|
|
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $99.7M | 3.21% | 910,340 -26,000 | -3% | -$2.85M |
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $89.6M | 2.88% | 148,015 +9,883 | +7% | +$5.98M |
|
7
Thermo Fisher Scientific
TMO
$186B
| $83.5M | 2.69% | 146,116 +5,986 | +4% | +$3.42M |
|
8
Johnson & Johnson
JNJ
$427B
| $83.4M | 2.69% | 516,652 | – | – |
|
9
Illumina
ILMN
$15.8B
| $78.7M | 2.53% | 193,963 -7,846 | -4% | -$3.18M |
|
10
Abbott
ABT
$231B
| $77.6M | 2.5% | 657,038 -93,959 | -13% | -$11.1M |
|
11
Medtronic
MDT
$119B
| $75.3M | 2.42% | 600,722 +54,000 | +10% | +$6.77M |
|
12
Biogen
BIIB
$19.4B
| $66.2M | 2.13% | 233,853 +24,729 | +12% | +$7M |
|
13
Eli Lilly
LLY
$657B
| $63.6M | 2.05% | 275,432 +18,871 | +7% | +$4.36M |
|
14
Merck
MRK
$210B
| $61.3M | 1.97% | 816,305 +274,602 | +51% | +$20.6M |
|
15
AbbVie
ABBV
$372B
| $56.5M | 1.82% | 524,213 -93,090 | -15% | -$10M |
|
|
16
Idexx Laboratories
IDXX
$51.8B
| $49.5M | 1.6% | 79,663 +44,849 | +129% | +$27.9M |
|
|
17
Vertex Pharmaceuticals
VRTX
$100B
| $49.5M | 1.59% | 273,046 -122,242 | -31% | -$22.2M |
|
|
18
AstraZeneca
AZN
$248B
| $48.8M | 1.57% | 812,927 +364,629 | +81% | +$21.9M |
|
|
19
Guardant Health
GH
$8.41B
| $48.5M | 1.56% | 387,984 +229,257 | +144% | +$28.7M |
|
20
Danaher
DHR
$147B
| $45.3M | 1.46% | 148,683 -17,557 | -11% | -$5.35M |
|
21
Cigna
CI
$80.3B
| $44.4M | 1.43% | 221,740 +10,722 | +5% | +$2.15M |
|
22
Stryker
SYK
$150B
| $39.7M | 1.28% | 150,500 | – | – |
|
23
Sarepta Therapeutics
SRPT
$1.78B
| $39.4M | 1.27% | 426,514 +233,290 | +121% | +$21.6M |
|
|
24
Rallybio
RLYB
$22.4M
| $37.6M | 1.21% | +2,308,672 | New | +$37.6M |
|
25
Bristol-Myers Squibb
BMY
$96B
| $36.2M | 1.17% | 612,236 -43,737 | -7% | -$2.59M |
|